Cocaine Addiction Clinical Trial
Official title:
The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
This study evaluates the use of N-acetylcysteine in the treatment of alcohol and cocaine use disorders. Alcohol users will be split in two groups, one will receive the active N-acetylcysteine and the other placebo. The same division will occur with cocaine users. The effects of N-acetylcysteine in adherence, abstinence, psychiatric symptoms and stress biomarkers will be evaluated.
N-acetylcysteine acts replenishing the human body glutathione storages. Glutathione is an
important antioxidant agent, and also modulates the N-methyl-D-aspartate (NMDA)
glutamatergic receptor. Glutamate has been associated with the neuroadaptation related to
substance use disorders, and thus it is considered a potential target for pharmacological
interventions regarding these disorders. N-acetylcysteine also interacts with the
cystine-glutamate antiporter on astrocytes hence increasing glutamate release into the
extracellular space.
N-acetylcysteine effects and its implications in the addiction disorders have been studied
initially with animal models. Glutamate levels normalization through N-acetylcysteine
reduced compulsive drug self-administration and drug-seeking behavior in mice. In addition,
there are promising results also with human subjects, showing benefits for cocaine, alcohol
and cannabis use disorders.
This study consists of a randomized, double-blind, placebo controlled trial with four arms:
alcohol users divided into NAC vs Placebo and cocaine users divided into NAC vs Placebo.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04336293 -
sTMS for Substance Use-disordered Veterans
|
N/A | |
| Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
| Completed |
NCT01822587 -
Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving
|
Phase 2 | |
| Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
| Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
| Completed |
NCT01651377 -
Pramipexole as a Treatment for Cocaine Dependence
|
Phase 1 | |
| Completed |
NCT02768441 -
Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots
|
Early Phase 1 | |
| Completed |
NCT02626494 -
Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction
|
Phase 4 | |
| Recruiting |
NCT02892851 -
Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.
|
N/A | |
| Not yet recruiting |
NCT01319214 -
Reducing Drug Craving Memories
|
N/A | |
| Recruiting |
NCT01259362 -
Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients
|
Phase 2 | |
| Completed |
NCT01211418 -
Integrative Meditation (IM) for Cocaine Addiction
|
N/A | |
| Recruiting |
NCT03423667 -
Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction
|
Phase 2 | |
| Completed |
NCT01984177 -
Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence
|
N/A | |
| Completed |
NCT01887366 -
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
|
Phase 2 | |
| Completed |
NCT01337297 -
Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction
|
Phase 1/Phase 2 | |
| Completed |
NCT01067846 -
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
|
N/A | |
| Completed |
NCT01651364 -
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
|
Phase 1 | |
| Completed |
NCT01929343 -
Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
|
Phase 2 | |
| Completed |
NCT01281202 -
Vigabatrin for the Treatment of Cocaine Dependency
|
Phase 2/Phase 3 |